According to Bio Protocol, the funding led by Maelstrom Fund and Animoca Brands supports its AI-driven decentralized biotech platform, aiming to accelerate drug discovery with blockchain and community-based participation.
Bio Protocol raised $6.9 million in seed funding from investors including Maelstrom Fund and Animoca Brands to advance its decentralized, AI-native biotech research framework. The platform introduces 'BioAgents,' decentralized AI agents that generate hypotheses, manage on-chain wallets, and direct community capital into experiments. All research activities are recorded onchain, ensuring transparent crediting of contributors. The project uses tokenized intellectual property, staking, and reward systems to align researchers, investors, and communities. Maelstrom founder Arthur Hayes described Bio Protocol as a potential “category-defining launchpad,” while Moonrock Capital’s Simon Dedic emphasized its role in addressing systemic inefficiencies in academic research.